thienamycins

Summary

Summary: Beta-lactam antibiotics that differ from PENICILLINS in having the thiazolidine sulfur atom replaced by carbon, the sulfur then becoming the first atom in the side chain. They are unstable chemically, but have a very broad antibacterial spectrum. Thienamycin and its more stable derivatives are proposed for use in combinations with enzyme inhibitors.

Top Publications

  1. ncbi Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals
    Endre Ludwig
    Szent László Hospital, Department of Clinical Microbiology and Infectiology, Budapest, Hungary
    Int J Antimicrob Agents 28:433-8. 2006
  2. ncbi The relationship between the daily dosage of the carbapenem meropenem (MEPM) and MEPM-resistant Pseudomonas aeruginosa
    Shin ichi Harashima
    Department of Clinical Research, Hara Doi Hospital, Fukuoka, Japan
    J Infect Chemother 14:219-22. 2008
  3. pmc Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae
    H Yigit
    Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Antimicrob Agents Chemother 45:1151-61. 2001
  4. pmc Biapenem inactivation by B2 metallo β-lactamases: energy landscape of the post-hydrolysis reactions
    Domenico L Gatti
    Department of Biochemistry and Molecular Biology, Wayne State University School of Medicine, Detroit, Michigan, United States of America
    PLoS ONE 7:e30079. 2012
  5. pmc Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory
    Johann D D Pitout
    Division of Microbiology, Calgary Laboratory Services, 9, 3535 Research Road NW, Calgary, Alberta, Canada T2L 2K8
    J Clin Microbiol 43:3129-35. 2005
  6. pmc Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing beta-lactamase KPC-2
    Hesna Yigit
    Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492, USA
    Antimicrob Agents Chemother 47:3881-9. 2003
  7. ncbi Protonation state and substrate binding to B2 metallo-beta-lactamase CphA from Aeromonas hydrofila
    F Simona
    SISSA, Via Beirut 2 4, 34014 Grignano, Trieste, Italy
    Proteins 69:595-605. 2007
  8. ncbi Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004
    Serhat Unal
    Section of Infectious Diseases, Department of Internal Medicine, Medical Faculty, Hacettepe University, Ankara 06100, Turkey
    Diagn Microbiol Infect Dis 53:265-71. 2005
  9. pmc Common mechanistic features among metallo-beta-lactamases: a computational study of Aeromonas hydrophila CphA enzyme
    Fabio Simona
    Laboratory of Computational Chemistry and Biochemistry, Department fur Chemie und Biochemie, Universitat Bern, Freiestrasse 3, CH 3012 Bern, Switzerland
    J Biol Chem 284:28164-71. 2009
  10. ncbi A metallo-beta-lactamase enzyme in action: crystal structures of the monozinc carbapenemase CphA and its complex with biapenem
    Gianpiero Garau
    Institut de Biologie Structurale Jean Pierre Ebel CNRS CEA UJF, 41, rue Jules Horowitz, F 38027 Grenoble Cedex 1, France
    J Mol Biol 345:785-95. 2005

Detail Information

Publications204 found, 100 shown here

  1. ncbi Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals
    Endre Ludwig
    Szent László Hospital, Department of Clinical Microbiology and Infectiology, Budapest, Hungary
    Int J Antimicrob Agents 28:433-8. 2006
    ..aeruginosa in Hungary...
  2. ncbi The relationship between the daily dosage of the carbapenem meropenem (MEPM) and MEPM-resistant Pseudomonas aeruginosa
    Shin ichi Harashima
    Department of Clinical Research, Hara Doi Hospital, Fukuoka, Japan
    J Infect Chemother 14:219-22. 2008
    ..aeruginosa in a hospital ward, and there were no side effects...
  3. pmc Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae
    H Yigit
    Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Antimicrob Agents Chemother 45:1151-61. 2001
    ..pneumoniae strain 1534 is mainly due to production of a novel Bush group 2f, class A, carbapenem-hydrolyzing beta-lactamase, KPC-1, although alterations in porin expression may also play a role...
  4. pmc Biapenem inactivation by B2 metallo β-lactamases: energy landscape of the post-hydrolysis reactions
    Domenico L Gatti
    Department of Biochemistry and Molecular Biology, Wayne State University School of Medicine, Detroit, Michigan, United States of America
    PLoS ONE 7:e30079. 2012
    ..This process leads to the formation of a bicyclic compound, as originally observed in the X-ray structure of the metallo β-lactamase CphA in complex with product...
  5. pmc Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory
    Johann D D Pitout
    Division of Microbiology, Calgary Laboratory Services, 9, 3535 Research Road NW, Calgary, Alberta, Canada T2L 2K8
    J Clin Microbiol 43:3129-35. 2005
    ..We recommend that all IPM-nonsusceptible P. aeruginosa isolates be routinely screened for MBL production using the EDTA disk screen test and that PCR confirmation be performed at a regional laboratory...
  6. pmc Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing beta-lactamase KPC-2
    Hesna Yigit
    Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492, USA
    Antimicrob Agents Chemother 47:3881-9. 2003
    ..This beta-lactamase is likely located on a transposon that is part of a conjugative plasmid and thus has a very high potential for dissemination...
  7. ncbi Protonation state and substrate binding to B2 metallo-beta-lactamase CphA from Aeromonas hydrofila
    F Simona
    SISSA, Via Beirut 2 4, 34014 Grignano, Trieste, Italy
    Proteins 69:595-605. 2007
    ..In both cases, the substrate is polarized as in aqueous solution. We conclude that addressing mechanistic issues on this class of enzymes requires a careful procedure to assign protonation states and substrate docking modes...
  8. ncbi Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004
    Serhat Unal
    Section of Infectious Diseases, Department of Internal Medicine, Medical Faculty, Hacettepe University, Ankara 06100, Turkey
    Diagn Microbiol Infect Dis 53:265-71. 2005
    ..8%) > ceftazidime (38.1%). The carbapenems appear to be a valuable option for the treatment of serious nosocomial infections caused by P. aeruginosa or Acinetobacter spp. over a broad geographical region...
  9. pmc Common mechanistic features among metallo-beta-lactamases: a computational study of Aeromonas hydrophila CphA enzyme
    Fabio Simona
    Laboratory of Computational Chemistry and Biochemistry, Department fur Chemie und Biochemie, Universitat Bern, Freiestrasse 3, CH 3012 Bern, Switzerland
    J Biol Chem 284:28164-71. 2009
    ..This mechanism provides an explanation for a variety of mutagenesis experiments and points to common functional facets across B2 and B1 MbetaLs...
  10. ncbi A metallo-beta-lactamase enzyme in action: crystal structures of the monozinc carbapenemase CphA and its complex with biapenem
    Gianpiero Garau
    Institut de Biologie Structurale Jean Pierre Ebel CNRS CEA UJF, 41, rue Jules Horowitz, F 38027 Grenoble Cedex 1, France
    J Mol Biol 345:785-95. 2005
    ..This will be relevant for the design of metallo-beta-lactamase inhibitors as well as of antibiotics that escape their hydrolytic activity...
  11. pmc Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock
    Fabio Silvio Taccone
    Department of Intensive Care, Erasme Hospital, Universite Libre de Bruxelles, Route de Lennik 808, 1070 Bruxelles, Belgium
    Crit Care 14:R126. 2010
    ..The aim of our study was to determine whether the first dose of piperacillin-tazobactam, ceftazidime, cefepime, and meropenem would result in adequate serum drug concentrations in patients with severe sepsis and septic shock...
  12. ncbi Meropenem monotherapy for the treatment of hospital-acquired pneumonia: results of a multicenter trial
    S J Berman
    St Francis Medical Center, Department of Infection Control, 1380 Liliha Street, Honolulu, HI 96813, USA
    J Chemother 16:362-71. 2004
    ..This study demonstrates that meropenem monotherapy is effective and well tolerated for patients with hospital-acquired pneumonia, including a subgroup of patients with ventilator-associated pneumonia...
  13. ncbi Antibiotic binding to monozinc CphA beta-lactamase from Aeromonas hydropila: quantum mechanical/molecular mechanical and density functional theory studies
    Dingguo Xu
    Department of Chemistry, University of New Mexico, Albuquerque, NM 87131, USA
    J Med Chem 48:6679-89. 2005
    ..The structure and dynamics of the substrate-enzyme complex provide valuable insights into the mode of catalysis in such enzymes that is central to the bacterial resistance to beta-lactam antibiotics...
  14. ncbi Catalytic mechanism of class B2 metallo-beta-lactamase
    Dingguo Xu
    Department of Chemistry, University of New Mexico, Albuquerque, New Mexico 87131
    J Biol Chem 281:8740-7. 2006
    ..The theoretical studies provided detailed insights into the catalytic strategy of this unique metallo-beta-lactamase...
  15. ncbi Results of two worldwide surveys into physician awareness and perceptions of extended-spectrum beta-lactamases
    H Goossens
    Department of Microbiology, University Hospital, Antwerp, Belgium
    Clin Microbiol Infect 10:760-2. 2004
    ..The surveys demonstrated that awareness of, and testing for, ESBLs is inconsistent...
  16. ncbi Novel mechanism of hydrolysis of therapeutic beta-lactams by Stenotrophomonas maltophilia L1 metallo-beta-lactamase
    J Spencer
    Department of Pathology and Microbiology, University of Bristol School of Medical Sciences, University Walk, Bristol BS8 1TD, United Kingdom
    J Biol Chem 276:33638-44. 2001
    ....
  17. ncbi Mechanical effects of the use of vancomycin and meropenem in acrylic bone cement
    Cecilia Persson
    Laboratorio di Tecnologia Medica, Istituti Ortopedici Rizzoli Bologna, IT 401 36 Italy
    Acta Orthop 77:617-21. 2006
    ..The antibiotics added to bone cements may, however, have detrimental effects on the mechanical properties of the cement...
  18. ncbi Novel IMP-1 metallo-beta-lactamase inhibitors can reverse meropenem resistance in Escherichia coli expressing IMP-1
    Joseph G Moloughney
    Department of Chemistry and Biochemistry, Montclair State University, 1 Normal Avenue, Montclair, NJ 07043, USA
    FEMS Microbiol Lett 243:65-71. 2005
    ..2 microM. NCI compounds, 20707, 140905 and 9746 sensitized a carbapenem-resistant laboratory strain of Escherichia coli to clinically achievable levels of meropenem...
  19. ncbi Meropenem: a review of its use in patients in intensive care
    M Hurst
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 59:653-80. 2000
    ..The incidence of drug-related nausea and vomiting is low and, in contrast to imipenem/cilastatin, does not increase with dose or speed of administration...
  20. ncbi Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution
    Jason A Roberts
    Burns, Trauma and Critical Care Research Centre, The University of Queensland, Brisbane, Australia
    J Antimicrob Chemother 64:142-50. 2009
    ....
  21. pmc Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections
    Chonghua Li
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    Antimicrob Agents Chemother 51:1725-30. 2007
    ..The findings for LRTI patients can be applied to optimize meropenem dose regimens to achieve clinical success and microbiological eradication in clinical practice...
  22. ncbi Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia
    Robert E Ariano
    Department of Pharmacy, St Boniface General Hospital, Manitoba, Canada
    Ann Pharmacother 39:32-8. 2005
    ..Pharmacodynamic investigations with antimicrobials define the relationship between the infecting organism and achievable drug concentrations with clinical outcome...
  23. ncbi Meropenem: a review of its use in the treatment of serious bacterial infections
    Claudine M Baldwin
    Wolters Kluwer Health Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Drugs 68:803-38. 2008
    ..Thus, meropenem continues to be an important option for the empirical treatment of serious bacterial infections in hospitalized patients...
  24. ncbi Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy
    Julia Langgartner
    Department of Internal Medicine I, University of Regensburg, Regensburg, Germany
    Intensive Care Med 34:1091-6. 2008
    ..The aim of this study was to test whether CI of meropenem achieves effective drug concentrations comparable to IB in patients treated by continuous renal replacement therapy (CRRT)...
  25. ncbi Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis
    A W Jenney
    Infectious Diseases Unit, Royal Darwin Hospital, Darwin, NT 0810, Australia
    Int J Antimicrob Agents 17:109-13. 2001
    ....
  26. pmc Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration
    F Thalhammer
    Department of Internal Medicine I, Division of Infectious Diseases, University of Vienna, A 1090 Vienna, Austria
    Antimicrob Agents Chemother 42:2417-20. 1998
    ..Based on these data, we conclude that patients with severe infections who are undergoing CVVH can be treated effectively with 1 g of meropenem every 8 h...
  27. ncbi Parenteral carbapenems
    P M Shah
    J W Goethe Universitaet, Arzt fuer Innere Medizin, Mikrobiologie und Infektion sepidemiologie, Biapenem Frankfurt, Germany
    Clin Microbiol Infect 14:175-80. 2008
    ..Imipenem, meropenem and ertapenem are licensed in the European Community and panipenem and biapenem are also available in Japan and South Korea. Other carbapenemes are under development...
  28. ncbi Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock
    J Karjagin
    Clinic of Anaesthesiology and Intensive Care, University of Tartu, Tartu, Estonia
    Clin Pharmacol Ther 83:452-9. 2008
    ....
  29. ncbi Biological and biomechanical effects of vancomycin and meropenem in acrylic bone cement
    Massimiliano Baleani
    Laboratorio di Tecnologia Medica, Istituti Ortopedici Rizzoli, Bologna, Italy
    J Arthroplasty 23:1232-8. 2008
    ..5 g of meropenem. Further investigations on this formulation with adjusted antibiotic amounts are, however, necessary to reach the optimal compromise between the antibacterial and the mechanical properties of the bone cement...
  30. ncbi Continuous infusion versus intermittent administration of meropenem in critically ill patients
    F Thalhammer
    Department of Internal Medicine I, University of Vienna, Austria
    J Antimicrob Chemother 43:523-7. 1999
    ..We conclude that CI of meropenem is equivalent to the IA regimen and is therefore suitable for treating critically ill patients. Further studies are necessary to compare the clinical effects of CI and IA in this patient group...
  31. ncbi Pharmacokinetics of meropenem in preterm neonates
    J G van Enk
    Departments of Neonatology and Pharmacy, VU Medical Center, Amsterdam, Netherlands
    Ther Drug Monit 23:198-201. 2001
    ..A 1-minute intravenous administration is feasible. Pharmacokinetic properties are comparable at day 5 compared with the first dose, and half-life is such that twice-daily administration of 15 mg/kg produces adequate serum concentrations...
  32. ncbi Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure
    M Valtonen
    Department of Medicine, Division of Infectious Diseases and Nephrology, Helsinki University Central Hospital, Helsinki, Finland
    J Antimicrob Chemother 45:701-4. 2000
    ..58 L/h in CVVH, CVVHDF 1 L/h and CVVHDF 2 L/h, respectively (P < 0.05 between CVVH and CVVHDF). Patients with renal failure on CVVHDF 1 or 2 L/h should be treated with meropenem 1 g bid; 500 mg tid may be enough for patients on CVVH...
  33. ncbi Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis
    Andrea Novelli
    Dipartimento di Farmacologia Preclinica e Clinica Mario Aiazzi Mancini, Universita di Firenze, Firenze, Italy
    Clin Pharmacokinet 44:539-49. 2005
    ....
  34. pmc Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration
    W A Krueger
    Department of Anesthesiology, Tubingen University Hospital, Tubingen, Germany
    Antimicrob Agents Chemother 42:2421-4. 1998
    ..Further reductions of the dosage might be appropriate for highly susceptible bacteria or when renal replacement therapies with lower clearances are applied...
  35. ncbi Antimicrobial effects of varied combinations of meropenem, sulbactam, and colistin on a multidrug-resistant Acinetobacter baumannii isolate that caused meningitis and bacteremia
    Chen Hsiang Lee
    Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan
    Microb Drug Resist 14:233-7. 2008
    ..Combined use of COL with MEM and/or SUL may provide good therapeutic options, even though MEM and SUL are in vitro resistance to the MDRAB...
  36. ncbi Tissue distribution of imipenem in critically ill patients
    Irmgard Tegeder
    Frankfurt Pharmacy Center, Johann Wolfgang Goethe University Clinic, Krankenhaus Nordwest, Theodor Stern Kai 7, 605290 Frankfurt am Main, Germany
    Clin Pharmacol Ther 71:325-33. 2002
    ..Most patients were >60 years old and had renal failure; most patients also had impaired liver, heart, or lung function...
  37. ncbi Antibacterial activity of carbapenem-based combinations againts multidrug-resistant Acinetobacter baumannii
    Pintip Pongpech
    Department of Biochemistry and Microbiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
    J Med Assoc Thai 93:161-71. 2010
    ..Antibacterial activity of two carbapenem-based combinations were explored in order to overcome the bacterial resistance...
  38. pmc Biochemical and structural characterization of the subclass B1 metallo-β-lactamase VIM-4
    Patricia Lassaux
    Laboratoire de Macromolecules Biologiques, Centre d Ingénierie des Protéines, Universite de Liege, Allée du 6 Août B6, Sart Tilman, 4000 Liege, Belgium
    Antimicrob Agents Chemother 55:1248-55. 2011
    ..Study of the thermal stability and the activity of the holo- and apo-VIM-4 enzymes revealed that Zn²+ ions have a pronounced stabilizing effect on the enzyme and are necessary for preserving the structure...
  39. ncbi Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results
    Philip J Turner
    Infection Discovery Department, AstraZenca, Alderley House, Alderley Park, Macclesfield, SK10 4TG Cheshire, UK
    Diagn Microbiol Infect Dis 60:185-92. 2008
    ..The continued need for surveillance studies such as MYSTIC in order that correct clinical decisions concerning antibiotic selection are made is once again demonstrated...
  40. ncbi Microbiological assay for the determination of meropenem in pharmaceutical dosage form
    Andreas S L Mendez
    Programa de Pós Graduação em Ciências Farmacêuticas, Faculdade de Farmacia, Universidade Federal do Rio Grande do Sul, Porto Alegre RS, Brazil
    J Pharm Biomed Anal 37:649-53. 2005
    ..The degraded samples were also analysed by the HPLC method. The proposed method allows the quantitation of meropenem in pharmaceutical dosage form and can be used for the drug analysis in routine quality control...
  41. ncbi An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 53:247-56. 2005
    ..Thus, antipseudomonal carbapenems such as meropenem and imipenem remain an effective treatment option...
  42. ncbi Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005)
    Paul R Rhomberg
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 57:207-15. 2007
    ....
  43. ncbi Activity of faropenem and imipenem for ciprofloxacin-resistant bacteria
    Laura J V Piddock
    Antimicrobial Agents Research Group, Division of Immunity and Infection, University of Birmingham, Birmingham B15 2TT, UK
    J Antimicrob Chemother 52:500-2. 2003
    ..To determine whether an association exists between ciprofloxacin and faropenem resistance in bacteria including multiply drug-resistant isolates...
  44. ncbi Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients
    Ruth Kitzes-Cohen
    Clinical Pharmacology and Infectious Diseases Unit, The Rappaport Faculty of Medicine, Carmel Medical Center, 7 Michal St, Technion, 34362, Haifa, Israel
    Int J Antimicrob Agents 19:105-10. 2002
    ..When pathogens were highly resistant (A. baumanii or P. aeruginosa) the T>MIC indices were lower...
  45. ncbi A comparison of the antimicrobial activity of meropenem and selected broad-spectrum antimicrobials tested against multi-drug resistant Gram-negative bacilli including bacteraemic Salmonella spp.: initial studies for the MYSTIC programme in India
    Ronald N Jones
    JMI Laboratories The Jones Group, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 20:426-31. 2002
    ..high levels of co-resistance between the tested beta-lactam agents and ciprofloxacin and the aminoglycosides, gentamicin and tobramycin. However, carbapenems such as meropenem, remain a therapeutic option...
  46. ncbi Carbapenems: a potent class of antibiotics
    David P Nicolau
    Hartford Hospital, Center for Anti Infective Research and Development, 80 Seymour Street, Hartford, Connecticut 06102 5037, USA
    Expert Opin Pharmacother 9:23-37. 2008
    ..Doripenem is an investigational carbapenem that has completed Phase III clinical trials and that has the potential to improve on this efficacy and minimize the emergence of resistance to the carbapenem class...
  47. ncbi Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens: a survey of project ICARE laboratories
    C D Steward
    Hospital Infections Program, Centers for Disease Control and Prevention, 1600 Clifton Rd, NE G08 Atlanta, GA 30333, USA
    Diagn Microbiol Infect Dis 38:59-67. 2000
    ..This highlights the need for monitoring how well susceptibility test systems in clinical laboratories detect emerging resistance...
  48. ncbi Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program
    Heather K Sun
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT, USA
    Crit Care Med 33:2222-7. 2005
    ..To compare the probability of achieving specific pharmacodynamic exposures of commonly used intravenous antibiotics for the empirical treatment of nosocomial pneumonia against those pathogens most commonly implicated in the disease...
  49. pmc Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii
    Glenn A Pankuch
    Department of Pathology, Hershey Medical Center, Hershey, PA 17033, USA
    Antimicrob Agents Chemother 52:333-6. 2008
    ..Subinhibitory meropenem and colistin concentrations of 0.03 to 64 and 0.06 to 8 microg/ml, respectively, showed synergy against 49 strains at 24 h...
  50. ncbi Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 61:203-13. 2008
    ....
  51. pmc Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection
    Sutep Jaruratanasirikul
    Department of Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkla 90110, Thailand
    Antimicrob Agents Chemother 49:1337-9. 2005
    ..For the treatment of infections caused by pathogens with intermediate resistance, a 3-h infusion of 2 g of meropenem every 8 h can provide concentrations in serum above the MIC of 16 microg/ml for almost 60% of an 8-h interval...
  52. ncbi Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain
    Jose R Hernandez
    Department of Microbiology, Faculty of Medicine, University of Seville, Av Sánchez Pizjuán S N, 41009 Seville, Spain
    Int J Antimicrob Agents 28:457-9. 2006
    ..Ertapenem activity was similar to that of imipenem and meropenem and better than that of the other antimicrobials tested. No differences in activity were observed regarding the origin of the isolates or type of ESBL produced...
  53. ncbi Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia
    Anthony M Nicasio
    Center for AntiInfective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    J Crit Care 25:69-77. 2010
    ....
  54. ncbi Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate
    John S Bradley
    Division of Infectious Diseases, Children s Hospital and Health Center, San Diego, CA 92123, USA
    Pediatr Infect Dis J 27:794-9. 2008
    ..Hospitalized neonates are exposed to antibiotic-resistant bacterial pathogens and develop nosocomial infections. Limited data are available regarding the neonatal pharmacokinetics of meropenem, a broad spectrum carbapenem antibiotic...
  55. pmc Comparison of the susceptibilities of Burkholderia pseudomallei to meropenem and ceftazidime by conventional and intracellular methods
    T J J Inglis
    The Division of Microbiology and Infectious Diseases, Western Australian Centre for Pathology and Medical Research, Nedlands, Western Australia, Australia
    Antimicrob Agents Chemother 48:2999-3005. 2004
    ..Further development of the intracellular MIC method is expected to help assess the efficacy of antimicrobial agents on this bacterial species in an intracellular setting...
  56. pmc Meropenem pharmacokinetics in the newborn
    John N van den Anker
    Department of Pediatrics, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA
    Antimicrob Agents Chemother 53:3871-9. 2009
    ..Treating clinicians need to balance dose choices for optimizing target attainment against potential toxicity. These findings require validation in clinical circumstances...
  57. ncbi Comparative review of the carbapenems
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Drugs 67:1027-52. 2007
    ..aeruginosa than meropenem. Clinical trials are required to establish the efficacy and safety of doripenem in moderate to severe infections, including nosocomial infections...
  58. ncbi Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program
    Philip J Turner
    Infection Discovery Department, AstraZeneca, SK10 4TG Macclesfield, Cheshire, UK
    Diagn Microbiol Infect Dis 56:341-4. 2006
    ..In particular, it examines the activity of meropenem against imipenem-resistant strains and vice versa. Meropenem proved to be active against up to a 3rd of imipenem-resistant strains...
  59. pmc Failure of quality control measures to prevent reporting of false resistance to imipenem, resulting in a pseudo-outbreak of imipenem-resistant Pseudomonas aeruginosa
    Y Carmeli
    Division of Infectious Diseases, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    J Clin Microbiol 36:595-7. 1998
    ..We recommend that this value be considered out of the quality-control range...
  60. ncbi Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem
    Shihomi Sakyo
    Department of Bacteriology and Bacterial Infection Control, Gunma University Graduate School of Medicine, Showa machi 3 39 22, Maebashi, Gunma 371 8511, Japan
    J Antibiot (Tokyo) 59:220-8. 2006
    ..The results shown in this report indicated that DRPM exhibited the greatest ability to prevent the emergence of the mutant...
  61. ncbi [Antimicrobial susceptibility of phenotypically extended spectrum beta-lactamase producing Pseudomonas aeruginosa and Acinetobacter baumannii isolates]
    Gokhan Metan
    Erciyes Universitesi Tip Fakultesi, Enfeksiyon Hastaliklari ve Klinik Mikrobiyoloji Anabilim Dali, Kayseri
    Mikrobiyol Bul 40:23-8. 2006
    ..aeruginosa and A. baumannii isolates were found highly resistant not only against the third and fourth generation cephalosporins, but also to the antibiotics currently used in the therapy including carbapenemes...
  62. ncbi Bacteriology and antimicrobial susceptibility of gram-positive cocci isolated from pus specimens of orofacial odontogenic infections
    T Kuriyama
    Department of Oral and Maxillofacial Surgery, Kanazawa University Graduate School of Medical Science, Ishikawa, Japan
    Oral Microbiol Immunol 17:132-5. 2002
    ..These results provide useful information for the treatment of orofacial odontogenic infections...
  63. ncbi [Evaluation of disk diffusion test for carbapenem sensitivity in Acinetobacter baumannii and Pseudomonas aeruginosa strains]
    Ozay Arikan Akan
    Ankara Universitesi, Tip Fakultesi Hastanesi, Merkez Laboratuvarlari, Ankara
    Mikrobiyol Bul 39:273-9. 2005
    ..Routine quality control studies for antibiotic susceptibility tests and close observation of suspicious results, is mandatory for each laboratory, in order to achieve good quality performance...
  64. ncbi Carbapenems in the USA: focus on doripenem
    Philip D Lister
    Creighton University School of Medicine, Department of Medical Microbiology and Immunology, 2500 California Plaza, Omaha, NE 68178, USA
    Expert Rev Anti Infect Ther 5:793-809. 2007
    ....
  65. ncbi Preferential selection of IMP and VIM metallo-beta-lactamases by imipenem in Pseudomonas aeruginosa
    Fiona Walsh
    University of Edinburgh, Edinburgh, UK
    Chemotherapy 53:407-9. 2007
    ..They developed resistance to both imipenem and meropenem. When the same mixed populations were exposed to meropenem, only the mixture containing the VIM beta-lactamases became resistant to both carbapenems...
  66. ncbi Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients
    Anthony D Harris
    Department of Epidemiology and Preventive Medicine, University of Maryland, VA Maryland Health Care System, 10 N Greene St BT111, Baltimore, MD 21201, USA
    Clin Infect Dis 34:340-5. 2002
    ..Antibiotics associated with ISPA are different from antibiotics associated with IRPA. The OR for imipenem as a risk factor for IRPA is less than that reported from studies in which control group selection was suboptimal...
  67. ncbi [Bactericidal activity of biapenem against various efflux system mutants of Pseudomonas aeruginosa]
    Tooru Hiraishi
    Pharmaceutical Research Center, Meiji Seika Kaisha, LTD 760 Morooka cho, Kohoku Ku, Yokohama, Kanagawa, 222 8567, Japan
    Jpn J Antibiot 55:67-76. 2002
    ..The bactericidal activity against P. aeruginosa KG5007, a strain overexpressing MexCD-OprJ, was observed only by biapenem. The bactericidal activity of biapenem was strong and not influenced by all of these three efflux systems...
  68. pmc Effect of porins and plasmid-mediated AmpC beta-lactamases on the efficacy of beta-lactams in rat pneumonia caused by Klebsiella pneumoniae
    Emma Padilla
    Servicio de Microbiologia, Hospital Son Dureta, IUNICS, Palma de Mallorca, Spain
    Antimicrob Agents Chemother 50:2258-60. 2006
    ..pneumoniae strain 12dp). No differences between these activities were seen with K. pneumoniae 12. Only meropenem showed an activity slightly better than that of imipenem with K. pneumoniae 12dp...
  69. ncbi In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals
    Carl Johan Fraenkel
    Department of Clinical Microbiology, Blekinge Hospital, Karlskrona, Sweden
    Scand J Infect Dis 38:853-9. 2006
    ..aeruginosa, Enterobacter and Proteus spp...
  70. ncbi Characterization of clinical isolates of Pseudomonas aeruginosa heterogeneously resistant to carbapenems
    Spyros Pournaras
    Department of Medical Microbiology, University of Thessalia, Mezourlo, Larissa, Greece
    J Med Microbiol 56:66-70. 2007
    ..These findings may be indicative that the use of carbapenems can lead to selection of P. aeruginosa resistant subpopulations that subsequently cause infections and result in treatment failure...
  71. ncbi Carbapenem-resistant Acinetobacter baumannii: an emerging threat for patients with post-neurosurgical meningitis
    Gokhan Metan
    Int J Antimicrob Agents 29:112-3. 2007
  72. ncbi Examination of cfiA-mediated carbapenem resistance in Bacteroides fragilis strains from a European antibiotic susceptibility survey
    J Soki
    Institute of Clinical Microbiology, Faculty of General Medicine, University of Szeged, H 6725 Szeged, Somogyi Béla tér 1, Hungary
    Int J Antimicrob Agents 28:497-502. 2006
    ..The major determinant of carbapenem resistance in Bacteroides fragilis is production of CfiA metallo-beta-lactamase via activation of the cfiA gene by IS elements (higher level resistance) or by activation of its putative own promoter...
  73. ncbi [Clinical efficacy of carbapenems in the treatment of destructive pneumonia and chronic purulent bronchitis]
    V I Sokolova
    Russian Academy of Post Graduate Medical Training, National Research Centre of Antibiotics, Moscow
    Antibiot Khimioter 48:21-4. 2003
  74. ncbi Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005)
    Lalitagauri M Deshpande
    JMI Laboratories, North Liberty, Iowa, USA
    Diagn Microbiol Infect Dis 56:367-72. 2006
    ..The escalating occurrence (0.35%) of serine carbapenemases could compromise the role of carbapenems and other beta-lactams in USA clinical practice although observed in only a few locations to date...
  75. pmc A novel insertion sequence, ISPA26, in oprD of Pseudomonas aeruginosa is associated with carbapenem resistance
    Joanna C Evans
    Antimicrob Agents Chemother 51:3776-7. 2007
  76. ncbi Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase
    C Pichardo
    Service of Infectious Diseases, Hospitales Universitarios Virgen del Rocio, Spain
    Clin Microbiol Infect 11:31-8. 2005
    ..05). Thus, in the guinea-pig pneumonia model, cefepime, imipenem and meropenem were each effective against the porin-deficient K. pneumoniae strain C2 and its derivative expressing the plasmid-mediated AmpC type beta-lactamase FOX-5...
  77. pmc Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing
    Fred C Tenover
    Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA
    Emerg Infect Dis 12:1209-13. 2006
    ..The recognition of carbapenem-resistant K. pneumoniae continues to challenge automated susceptibility systems...
  78. ncbi Emerging resistance to carbapenems in a tertiary care hospital in north India
    Ekta Gupta
    Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India
    Indian J Med Res 124:95-8. 2006
    ..We therefore retrospectively evaluated the antibiotic susceptibility pattern to these agents amongst various clinical isolates in a tertiary care hospital in north India...
  79. ncbi Carbapenem resistance in clinical isolates of Pseudomonas aeruginosa
    F Walsh
    University of Edinburgh, United Kingdom
    J Chemother 19:376-81. 2007
    ..Therefore, the resistance mechanisms identified by development of carbapenem resistance in vitro are not sufficient to understand carbapenem resistance development in clinical isolates...
  80. ncbi [Metallo-beta-lactamase-producing gram-negative rods isolated from inpatients and outpatients, detected using Etest MBL]
    Alicja Rokosz
    Katedra i Zakład Mikrobiologii Lekarskiej AM w Warszawie
    Med Dosw Mikrobiol 58:73-81. 2006
    ..MBL-producing strains of Gram-negative rods, detected by phenotypic Etest MBL method, will be verified with genetic procedures...
  81. ncbi Prevalence and mechanisms of decreased susceptibility to carbapenems in Klebsiella pneumoniae isolates
    Soo Young Kim
    Department of Clinical Pathology, College of Medicine, The Catholic University of Korea, St Vincent s Hospital, Suwon 442 723, South Korea
    Diagn Microbiol Infect Dis 57:85-91. 2007
    ..pneumoniae when bla(GES-3), bla(TEM-11), bla(SHV-12), bla(OXA-17), and/or bla(DHA-1) are produced in combination with porin loss. In addition, to our knowledge, this is the 1st report of bla(OXA-17) in Enterobacteriaceae...
  82. ncbi Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases
    Chen Hsiang Lee
    Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical Center, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta Pei Road, Niao Sung, Kaohsiung 833, Taiwan
    J Antimicrob Chemother 60:410-3. 2007
    ..The study aimed to characterize the genetic basis of flomoxef and collateral ertapenem resistance in a clinical isolate of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae (ESBL-KP) after flomoxef exposure...
  83. ncbi Evaluation of dipicolinic acid for detection of IMP- or VIM- type metallo-beta-lactamase-producing Pseudomonas aeruginosa clinical isolates
    Soichiro Kimura
    Department of Microbiology and Infectious Disease, Toho University School of Medicine, Tokyo 1438540, Japan
    Diagn Microbiol Infect Dis 53:241-4. 2005
    ..In disk diffusion testing, expansion of growth inhibitory zone of these clinical isolates was clearly observed. Thus, DPA could be useful in the detection for MBL-producing P. aeruginosa clinical isolates...
  84. ncbi The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains
    Ilknur Erdem
    Clinic of Infectious Disease and Clinical Microbiology, Haydarpasa Numune Training and Research Hospital, No 153 4, 81150 Baglarbasi, Istanbul, Turkey
    Int J Antimicrob Agents 20:384-6. 2002
    ..2%) and ciprofloxacin and imipenem against 1 strain (3.1%). Levofloxacin and imipenem or meropenem were not synergistic for against any strain. None of the combinations showed an antagonistic effect...
  85. ncbi [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated at Kochi Municipal Central Hospital in the last 3 years]
    Yoshitsugu Nasu
    Infection Control Committee, Kochi Municipal Central Hospital
    Jpn J Antibiot 57:438-48. 2004
    ..6. Of 388 isolates, 34 isolates were resistant to imipenem, but no positive isolate was found in screening of metallo-beta-lactamase-producing bacteria...
  86. ncbi [Participation of metallo-beta-lactamases in resistance to imipenem and meropenem in clinical strains of Pseudomonas aeruginosa and Acinetobacter spp]
    Paweł Sacha
    Zakładu Diagnostyki Mikrobiologicznej Akademii Medycznej w Białymstoku
    Wiad Lek 61:30-6. 2008
    ..The aim of this study was to determine participation of MBLs in resistance to carbapenems of P. aeruginosa and Acinetobacter spp. and antimicrobial susceptibility to antibiotics...
  87. ncbi [Carbapenemase detection in Acinetobacter baumannii clones resistant to imipenem]
    Lucía Gallego
    Departamento de Inmunologia, Microbiologia y Parasitologia, Facultad de Medicina y Odontologia, Universidad del Pais Vasco, Bilbao, Vizcaya, Spain
    Enferm Infecc Microbiol Clin 22:262-6. 2004
    ....
  88. ncbi Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases
    Leticia R Moczygemba
    College of Pharmacy, The University of Texas at Austin, USA
    Clin Ther 26:1800-7. 2004
    ....
  89. pmc Discrepancies and interpretation problems in susceptibility testing of VIM-1-producing Klebsiella pneumoniae isolates
    P Giakkoupi
    Department of Microbiology, National School of Public Health, 196 Alexandras Ave, Athens 11521, Greece
    J Clin Microbiol 43:494-6. 2005
    ..Significant discrepancies were observed in the determination of susceptibility to imipenem and meropenem. Interpretation problems by the automated systems were also noted...
  90. pmc Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation
    Ben M Lomaestro
    Albany Medical Center Hospital, 43 New Scotland Ave, Albany, NY 12208, USA
    Antimicrob Agents Chemother 49:461-3. 2005
    ..5 g of imipenem-cilastatin (I-C) q6h (1-h infusion). For other pathogens, 500 mg of MEM q8h was equivalent or superior to I-C...
  91. ncbi [Activity of cephems and carbapenems against clinically isolated Mycobacterium abscessus]
    Kunihiko Ito
    Research Division, Research Institute of Tuberculosis, Japan Anti Tuberculosis Association, 3 1 24, Matsuyama, Kiyose shi, Tokyo 204 8533, Japan
    Kekkaku 78:587-90. 2003
    ..From this study, it is concluded that FMOX, IPM, PAPM and MEPM can be clinically useful drugs in the treatment of the disease due to M. abscessus...
  92. ncbi Pseudomonas aeruginosa strains harbouring an unusual blaVIM-4 gene cassette isolated from hospitalized children in Poland (1998-2001)
    Jan Patzer
    The Children s Memorial Health Institute, Warsaw, Poland
    J Antimicrob Chemother 53:451-6. 2004
    ..These strains were investigated further to determine the mechanism of resistance...
  93. ncbi [In vitro antibacterial activity and beta-lactamase stability of meropenem]
    Antonia Poiata
    Facultatea de Farmacie, Disciplina Microbiologie, Universitatea de Medicină şi Farmacie Gr T Popa, Iasi
    Rev Med Chir Soc Med Nat Iasi 107:589-94. 2003
    ..EDTA, FeCl2 and CuCl2 were evaluated as IMP-1 inhibitors. The method is helpful for screening of IMP-1 producers in daily clinical activity...
  94. ncbi [The prevalence of beta-lactamase negative ampicillin resistant Haemophilus influenzae in Mie Prefecture]
    Tokuyoshi Maruyama
    Division of Blood Transfusion, Mie University Hospital
    Kansenshogaku Zasshi 78:891-7. 2004
    ..In this study, six (8.1%) of 74 isolates were found to be BLNAR, and all of these six isolates were derived from patients of 5 year-old or younger...
  95. ncbi [Investigation of the in-vitro effectiveness of ertapenem against Pseudomonas aeruginosa strains isolated from intensive care unit patients]
    Abdullah Kilic
    GATA Mikrobiyoloji ve Klinik Mikrobiyoloji Anabilim Dali, Ankara
    Mikrobiyol Bul 38:355-62. 2004
    ..In case of confirmation of our results by larger scale studies, the empiric treatment of ICU infections caused by P. aeruginosa with ertapenem, should be carefully evaluated...
  96. ncbi Effect of basic amino acids on susceptibility to carbapenems in clinical Pseudomonas aeruginosa isolates
    Hideaki Muramatsu
    Division of Pharmacy, Hamamatsu University School of Medicine, Hamamatsu, Japan
    Int J Med Microbiol 293:191-7. 2003
    ..For a better prediction of antibiotic efficacy, it may be important to evaluate the susceptibility for each carbapenem individually...
  97. ncbi In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections
    S Nomura
    Department of Nutrition, Nakamura Gakuen University, Fukuoka, Japan
    J Chemother 14:155-60. 2002
    ..Thus S-4661 possesses potent and well-balanced wide-spectrum antibacterial activity against various urological pathogens...
  98. ncbi Prevalence of multi and pan drug resistant Pseudomonas aeruginosa with respect to ESBL and MBL in a tertiary care hospital
    S Jayakumar
    Department of Microbiology, PSG Institute of Medical Sciences and Research, Coimbotore
    Indian J Pathol Microbiol 50:922-5. 2007
    ..Majority of the PDRPA isolates were MBL producers which have propensity to spread to other bacteria...
  99. ncbi Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program
    Srividya Kotapati
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA
    Surg Infect (Larchmt) 6:297-304. 2005
    ..375 g q6h and 4.5 g q8h in the empiric treatment of secondary peritonitis...
  100. pmc In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates
    Hannah M Wexler
    Medical and Research Services, Greater Los Angeles Veterans Administration Health Care Services, California, USA
    Antimicrob Agents Chemother 49:4413-7. 2005
    ..Doripenem appears to have excellent activity against a broad range of anaerobes...
  101. ncbi Comparison of antimicrobial resistance of Acinetobacter baumannii clinical isolates from Shanghai and Hong Kong
    Thomas K W Ling
    Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, SAR, China
    Med Princ Pract 14:338-41. 2005
    ..To compare the antimicrobial resistance patterns of Acinetobacter baumannii isolates from Shanghai and Hong Kong...

Research Grants9

  1. STRUCTURE/FUNCTION OF AN ION MOTIVE ATPASE
    DOMENICO GATTI; Fiscal Year: 2001
    ..Analysis of the similarities and differences between these two enzymes will further our understanding of how ions are transported across biological membranes. ..
  2. Structure, mechanism and evolution of KDO8P synthase
    DOMENICO GATTI; Fiscal Year: 2007
    ..abstract_text> ..
  3. REGULATION OF NEUTROPHIL OXIDATIVE RESPONSES IN TRAUMA
    Joseph Solomkin; Fiscal Year: 2004
    ..Together, these studies will define potential points for therapeutic intervention and provide important insight into regulation of the acute inflammatory response. ..
  4. BACTERIAL MODULATION OF LUNG INFLAMMATORY RESPONSE
    Thomas Russo; Fiscal Year: 2004
    ..g. hemolysin) and bacterially induced host response elements in directly mediating the pathogenesis of lung injury. ..
  5. Study design importance in analyzing emerging pathogens
    Anthony Harris; Fiscal Year: 2005
    ..The second aim will be done by combining epidemiological relatedness and molecular relatedness through pulse-field gel electrophoresis of ESBL cultures to quantify the importance of patient to patient transmission. ..
  6. Novel Targets for Treatment of Pseudomonas aeruginosa
    Philip Lister; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  7. New Nosocomial Interventions to Decrease Antimicrobial Resistance Transmission
    Anthony Harris; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  8. Polymyxin-resistant Pseudomonas in CF Lung Infection
    Samuel M Moskowitz; Fiscal Year: 2010
    ..An interdisciplinary study of polymyxin resistant Pseudomonas from patients with cystic fibrosis is proposed to pinpoint the bacterial genes responsible for this resistance, so that management strategies may be devised to overcome it. ..